Glymidine sodium (glycodiazine; trade name Gondafon) is a sulfapyrimidine derivative with antihyperglycemic/antidiabetic activity. It is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin.
Physicochemical Properties
| Molecular Formula | C13H14N3O4S-.NA+ |
| Molecular Weight | 331.32276 |
| Exact Mass | 331.06 |
| Elemental Analysis | C, 47.13; H, 4.26; N, 12.68; Na, 6.94; O, 19.32; S, 9.68 |
| CAS # | 3459-20-9 |
| Related CAS # | 339-44-6 (free acid);3459-20-9 (sodium); |
| PubChem CID | 23691021 |
| Appearance | Solid powder |
| Density | 1.354g/cm3 |
| Boiling Point | 515.1ºC at 760mmHg |
| Melting Point | 221-226° |
| Flash Point | 265.4ºC |
| LogP | 2.242 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 7 |
| Heavy Atom Count | 22 |
| Complexity | 399 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | [Na+].COCCOC1C=NC([N-]S(C2C=CC=CC=2)(=O)=O)=NC=1 |
| InChi Key | HCLFWAHLVGHDOL-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C13H14N3O4S.Na/c1-19-8-9-20-11-4-2-5-12(10-11)21(17,18)16-13-14-6-3-7-15-13;/h2-7,10H,8-9H2,1H3;/q-1;+1 |
| Chemical Name | sodium;[3-(2-methoxyethoxy)phenyl]sulfonyl-pyrimidin-2-ylazanide |
| Synonyms | BS 717; Glycanol; Glycodiazin; Glycodiazine; Glycodiazine sodium; Glyconormal; Glymidine; Glymidine sodium; Glymidine sodium salt; Gondafon; Lycanol; Redul; Redul IF; Redul sodium; SH 717; |
| HS Tariff Code | 2934.99.03.00 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References | :The role of endogenous lipid in gluconeogenesis and ketogenesis of perfused rat liver. Eur J Biochem. 1969;9(2):182-188. |
Solubility Data
| Solubility (In Vitro) | DMSO : ~125 mg/mL (~377.28 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (6.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0182 mL | 15.0912 mL | 30.1823 mL | |
| 5 mM | 0.6036 mL | 3.0182 mL | 6.0365 mL | |
| 10 mM | 0.3018 mL | 1.5091 mL | 3.0182 mL |